Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Free Cash Flow (2018 - 2025)

TransMedics (TMDX) has 8 years of Free Cash Flow data on record, last reported at $76.5 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 42.8% year-over-year to $76.5 million; the TTM value through Dec 2025 reached $191.1 million, up 308.82%, while the annual FY2025 figure was $191.1 million, 308.82% up from the prior year.
  • Free Cash Flow reached $76.5 million in Q4 2025 per TMDX's latest filing, up from $27.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $133.7 million in Q4 2024 and bottomed at -$141.8 million in Q4 2023.
  • Average Free Cash Flow over 5 years is -$265450.0, with a median of -$8.5 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: plummeted 2910.52% in 2023, then skyrocketed 1269.58% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$9.8 million in 2021, then soared by 151.35% to $5.0 million in 2022, then tumbled by 2910.52% to -$141.8 million in 2023, then skyrocketed by 194.3% to $133.7 million in 2024, then plummeted by 42.8% to $76.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $76.5 million in Q4 2025, $27.1 million in Q3 2025, and $117.4 million in Q2 2025.